BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 29281999)

  • 1. Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer.
    Mercogliano MF; Inurrigarro G; De Martino M; Venturutti L; Rivas MA; Cordo-Russo R; Proietti CJ; Fernández EA; Frahm I; Barchuk S; Allemand DH; Figurelli S; Deza EG; Ares S; Gercovich FG; Cortese E; Amasino M; Guzmán P; Roa JC; Elizalde PV; Schillaci R
    BMC Cancer; 2017 Dec; 17(1):895. PubMed ID: 29281999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invasive micropapillary carcinoma of the breast: a clinicopathologic study of 103 cases of an unusual and highly aggressive variant of breast carcinoma.
    Gokce H; Durak MG; Akin MM; Canda T; Balci P; Ellidokuz H; Demirkan B; Gorken IB; Sevinc AI; Kocdor MA; Saydam S; Harmancioglu O
    Breast J; 2013; 19(4):374-81. PubMed ID: 23714006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in Prognostic Factors and Failure Patterns Between Invasive Micropapillary Carcinoma and Carcinoma With Micropapillary Component Versus Invasive Ductal Carcinoma of the Breast: Retrospective Multicenter Case-Control Study (KROG 13-06).
    Yu JI; Choi DH; Huh SJ; Cho EY; Kim K; Chie EK; Ha SW; Park IA; Ahn SJ; Lee JS; Shin KH; Kwon Y; Kim YB; Suh CO; Koo JS; Kim JH; Jeong BG; Kim IA; Lee JH; Park W
    Clin Breast Cancer; 2015 Oct; 15(5):353-61.e1-2. PubMed ID: 25776197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invasive micropapillary carcinoma of the breast has a better long-term survival than invasive ductal carcinoma of the breast in spite of its aggressive clinical presentations: a comparison based on large population database and case-control analysis.
    Chen H; Wu K; Wang M; Wang F; Zhang M; Zhang P
    Cancer Med; 2017 Dec; 6(12):2775-2786. PubMed ID: 29072365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of invasive micropapillary and triple negative invasive ductal carcinoma of the breast.
    Chen HL; Ding A
    Breast; 2015 Dec; 24(6):723-31. PubMed ID: 26392199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
    Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
    Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invasive micropapillary carcinoma of the breast had poor clinical characteristics but showed no difference in prognosis compared with invasive ductal carcinoma.
    Li G; Yang S; Yao J; Wang Z; Yao G; Liu M; Ye C
    World J Surg Oncol; 2016 Aug; 14(1):207. PubMed ID: 27492008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of CD146 and microvessel density (MVD) in invasive micropapillary carcinoma of the breast: Comparative study with invasive ductal carcinoma-not otherwise specified.
    Li W; Yang D; Wang S; Guo X; Lang R; Fan Y; Gu F; Zhang X; Niu Y; Yan X; Fu L
    Pathol Res Pract; 2011 Dec; 207(12):739-46. PubMed ID: 22051146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.
    Ulas A; Kos T; Avci N; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
    Asian Pac J Cancer Prev; 2015; 16(4):1643-9. PubMed ID: 25743846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinicopathological significance of CD44+/CD24-/low and CD24+ tumor cells in invasive micropapillary carcinoma of the breast.
    Li W; Liu F; Lei T; Xu X; Liu B; Cui L; Wei J; Guo X; Lang R; Fan Y; Gu F; Tang P; Zhang X; Fu L
    Pathol Res Pract; 2010 Dec; 206(12):828-34. PubMed ID: 20977976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in prognostic factors and patterns of failure between invasive micropapillary carcinoma and invasive ductal carcinoma of the breast: matched case-control study.
    Yu JI; Choi DH; Park W; Huh SJ; Cho EY; Lim YH; Ahn JS; Yang JH; Nam SJ
    Breast; 2010 Jun; 19(3):231-7. PubMed ID: 20304650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in breast: A meta-analysis of PSM studies.
    Ye F; Yu P; Li N; Yang A; Xie X; Tang H; Liu P
    Breast; 2020 Jun; 51():11-20. PubMed ID: 32172190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
    Hergueta-Redondo M; Sarrio D; Molina-Crespo Á; Vicario R; Bernadó-Morales C; Martínez L; Rojo-Sebastián A; Serra-Musach J; Mota A; Martínez-Ramírez Á; Castilla MÁ; González-Martin A; Pernas S; Cano A; Cortes J; Nuciforo PG; Peg V; Palacios J; Pujana MÁ; Arribas J; Moreno-Bueno G
    Oncotarget; 2016 Aug; 7(35):56295-56308. PubMed ID: 27462779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive micropapillary carcinoma of the breast had no difference in prognosis compared with invasive ductal carcinoma: a propensity-matched analysis.
    Hao S; Zhao YY; Peng JJ; Ren F; Yang WT; Yu KD; Shao ZM
    Sci Rep; 2019 Jan; 9(1):286. PubMed ID: 30670771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The reversed apical pattern of MUC1 expression is characteristics of invasive micropapillary carcinoma of the breast.
    Li YS; Kaneko M; Sakamoto DG; Takeshima Y; Inai K
    Breast Cancer; 2006; 13(1):58-63. PubMed ID: 16518063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic study of invasive micropapillary carcinoma of the breast.
    Tang SL; Yang JQ; Du ZG; Tan QW; Zhou YT; Zhang D; Lv Q
    Oncotarget; 2017 Jun; 8(26):42455-42465. PubMed ID: 28418916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic markers for invasive micropapillary carcinoma of the breast: a population-based analysis.
    Chen AC; Paulino AC; Schwartz MR; Rodriguez AA; Bass BL; Chang JC; Teh BS
    Clin Breast Cancer; 2013 Apr; 13(2):133-9. PubMed ID: 23246269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invasive micropapillary mucinous carcinoma of the breast is associated with poor prognosis.
    Liu F; Yang M; Li Z; Guo X; Lin Y; Lang R; Shen B; Pringle G; Zhang X; Fu L
    Breast Cancer Res Treat; 2015 Jun; 151(2):443-51. PubMed ID: 25953688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.